References
- Drain S, Catherwood MA, Orr N, Galligan L, Rea IM, Hodkinson C, et al. ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma 2009; 50: 566–570
- Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, et al. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 2007; 137: 454–456
- Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P. Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica 2007; 92: 277–278
- Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 2008; 18: 383–389
- Kroetz D L, Pauli-Magnus C, Hodges L M, Huang C C, Kawamoto M, Johns S J, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481–494
- Nuessler V, Gieseler F, Gullis E, Pelka-Fleischer R, Stotzer O, Zwierzina H, et al. Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease. Leukemia 1997; 11(Suppl 5)S10–S14
- Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001; 115: 895–902
- Friedenberg W R, Rue M, Blood E A, Dalton W S, Shustik C, Larson R A, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006; 106: 830–838
- Hui R C, Francis R E, Guest S K, Costa J R, Gomes A R, Myatt S S, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 2008; 7: 670–678
- Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81: 824–831
- Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy J D, Jr. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 2008; 14: 4821–4829